SEARCH

SEARCH BY CITATION

References

  • 1
    Pack AM, Gidal B, Vazquez B. Bone disease associated with antiepileptic drugs. Cleve Clin J Med. 2004;71(Suppl 2):S428.
  • 2
    Pack AM. Treatment of epilepsy to optimize bone health. Curr Treat Options Neurol. 2011;13(4):34654.
  • 3
    Shah SC, Sharma RK, Hemangini Chitle AR. Rifampicin induced osteomalacia. Tubercle. 1981;62(3):2079.
  • 4
    Brodie MJ, Boobis AR, Hillyard CJ, Abeyasekera G, Stevenson JC, MacIntyre I, Park BK. Effect of rifampicin and isoniazid on vitamin D metabolism. Clin Pharmacol Ther. 1982;32(4):52530.
  • 5
    Peterson P, Gray P, Tolman KG. Calcium balance in drug-induced osteomalacia: response to vitamin D. Clin Pharmacol Ther. 1976;19(1):637.
  • 6
    Bhan A, Rao AD, Rao DS. Osteomalacia as a result of vitamin D deficiency. Endocrinol Metab Clin North Am 2010;39(2), 32131.
  • 7
    Pascussi JM, Robert A, Nguyen M, Walrant-Debray O, Garabedian M, Martin P, Pineau T, Saric J, Navarro F, Maurel P. Vilarem MJ. 2005; Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J. Clin. Invest. 115(1):17786.
  • 8
    Xu Y, Hashizume T, Shuhart MC, Davis CL, Nelson WL, Sakaki T, Kalhorn TF, Watkins PB, Schuetz EG, Thummel KE. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1(,25-dihydroxyvitamin D3: implications for drug-induced osteomalacia. Mol. Pharmacol. 2006;69(1):5665.
  • 9
    Zhou C, Assem M, Tay JC, Watkins PB, Blumberg B, Schuetz EG, Thummel KE. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J. Clin. Invest. 2006;116(6):170312.
  • 10
    Brodie MJ, Boobis AR, Dollery CT, Hillyard CJ, Brown DJ, MacIntyre I, Park BK. Rifampicin and vitamin D metabolism. Clin. Pharmacol. Ther. 1980;27(6):8104.
  • 11
    Lee RH, Lyles KW, Colon-Emeric C. A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. Am J Geriatr Pharmacother. 2010;8(1):3446.
  • 12
    DeLuca HF. Evolution of our understanding of vitamin D. Nutr. Rev. 2008;66(10 Suppl 2):S7387.
  • 13
    Burt R, Freston JW, Tolman KG. The influence of phenobarbital on biotransformation of 25-hydroxycholecalciferol. J Clin Pharmacol. 1976;16(8–9):3938.
  • 14
    Eastwood JB, de Wardener HE, Gray RW, Lemann JL Jr. Normal plasma-1,25-(OH)2-vitamin-D concentrations in nutritional osteomalacia. Lancet. 1979;1(8131):13778.
  • 15
    Pack AM, Morrell MJ. Epilepsy and bone health in adults. Epilepsy Behav. 2004;5(Suppl 2):S249.
  • 16
    Sakaki T, Sawada N, Komai K, Shiozawa S, Yamada S, Yamamoto K, Ohyama Y, Inouye K. Dual metabolic pathway of 25-hydroxyvitamin D3 catalyzed by human CYP24. Eur. J. Biochem. 2000;267(20):615865.
  • 17
    Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem. Sci. 2004;29(12):66473.
  • 18
    Hashizume T, Xu Y, Mohutsky MA, Alberts J, Hadden C, Kalhorn TF, Isoherranen N, Shuhart MC, Thummel KE. Identification of human UDP-glucuronosyltransferases catalyzing hepatic 1alpha,25-dihydroxyvitamin D3 conjugation. Biochem Pharmacol. 2008;75(5):124050.
  • 19
    Christakos S, Ajibade DV, Dhawan P, Fechner AJ, Mady LJ. Vitamin D: Metabolism. Endocrinol. Metab. Clin. North Am. 2010;39(2):24353.
  • 20
    Ohyama Y, Yamasaki T. Eight cytochrome P450s catalyze vitamin D metabolism. Front. Biosci. 2004;9:300718.
  • 21
    Wang Z, Lin YS, Zheng XE, Senn T, Hashizume T, Scian M, Dickmann LJ, Nelson SD, Baillie TA, Hebert MF, Blough D, Davis CL, Thummel KE. An Inducible Cytochrome P450 3A4-Dependent Vitamin D Catabolic Pathway. Mol Pharmacol. 2012;81(4):498509.
  • 22
    Wang Z, Senn T, Kalhorn T, Zheng XE, Zheng S, Davis CL, Hebert MF, Lin YS, Thummel KE. Simultaneous measurement of plasma vitamin D(3) metabolites, including 4beta,25-dihydroxyvitamin D(3), using liquid chromatography-tandem mass spectrometry. Anal Biochem. 2011;418(1):12633.
  • 23
    Ryan MJ, Johnson G, Kirk J, Fuerstenberg SM, Zager RA, Torok-Storb B. HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int. 1994;45(1):4857.
  • 24
    Zheng XE, Wang Z, Liao MZ, Lin YS, Shuhart MC, Schuetz EG, Thummel KE. Human PXR-mediated induction of intestinal CYP3A4 attenuates 1alpha,25-dihydroxyvitamin D(3) function in human colon adenocarcinoma LS180 cells. Biochem Pharmacol. 2012;84(3):391401.
  • 25
    Houston JB. Drug metabolite kinetics. Pharmacol Ther. 1981;15(3):52152.
  • 26
    Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, Thummel KE. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther. 1996;60(1):1424.
  • 27
    Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther. 1996;59(5):491502.
  • 28
    Karaaslan Y, Haznedaroglu S, Ozturk M. Osteomalacia associated with carbamazepine/valproate. Ann Pharmacother. 2000;34(2):2645.
  • 29
    Andress DL, Ozuna J, Tirschwell D, Grande L, Johnson M, Jacobson AF, Spain W. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol. 2002;59(5):7816.
  • 30
    Petty SJ, O'Brien TJ, Wark JD. Anti-epileptic medication and bone health. Osteoporos Int. 2007;18(2):12942.
  • 31
    Carbone LD, Johnson KC, Robbins J, Larson JC, Curb JD, Watson K, Gass M, Lacroix AZ. Antiepileptic drug use, falls, fractures, and BMD in postmenopausal women: findings from the women's health initiative (WHI). J Bone Miner Res. 2010;25(4):87381.
  • 32
    Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest. 1998;102(5):101623.
  • 33
    Cheng J, Ma X, Gonzalez FJ. Pregnane X receptor- and CYP3A4-humanized mouse models and their applications. Br J Pharmacol. 2011;163(3):4618.
  • 34
    Goodwin B, Hodgson E, D'Costa DJ, Robertson GR, Liddle C. Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol Pharmacol. 2002;62(2):35965.
  • 35
    Burk O, Koch I, Raucy J, Hustert E, Eichelbaum M, Brockmoller J, Zanger UM, Wojnowski L. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem. 2004;279(37):3837985.
  • 36
    Gascon-Barre M, Demers C, Mirshahi A, Neron S, Zalzal S, Nanci A. The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells. Hepatology. 2003;37(5):103442.
  • 37
    Vicchio D, Yergey A, O'Brien K, Allen L, Ray R, Holick M. Quantification and kinetics of 25-hydroxyvitamin D3 by isotope dilution liquid chromatography/thermospray mass spectrometry. Biol Mass Spectrom. 1993;22(1):538.
  • 38
    Schuster I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim. Biophys. Acta. 2011;1814(1):18699.
  • 39
    Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther. 1997;283(3):155262.
  • 40
    von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivisto KT. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther. 2004;75(3):17283.
  • 41
    Higashi T, Horike M, Kikuchi R, Shimada K. In vitro and in vivo glucuronidation of 24,25-dihydroxyvitamin D3. Steroids. 1999;64(10):71525.